HQY vs. COLL
Compare and contrast key facts about HealthEquity, Inc. (HQY) and Collegium Pharmaceutical, Inc. (COLL).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: HQY or COLL.
Correlation
The correlation between HQY and COLL is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Maximize Your Portfolio’s Potential
Does your portfolio have the optimal asset allocation aligned with your goals? Find it out with our portfolio optimizer
Try portfolio optimization nowPerformance
HQY vs. COLL - Performance Comparison
Key characteristics
HQY:
0.42
COLL:
-0.66
HQY:
0.74
COLL:
-0.67
HQY:
1.11
COLL:
0.91
HQY:
0.46
COLL:
-0.64
HQY:
1.25
COLL:
-1.19
HQY:
12.20%
COLL:
22.15%
HQY:
40.65%
COLL:
43.24%
HQY:
-60.65%
COLL:
-73.59%
HQY:
-20.24%
COLL:
-34.85%
Fundamentals
HQY:
$7.83B
COLL:
$888.44M
HQY:
$1.09
COLL:
$1.86
HQY:
83.10
COLL:
14.87
HQY:
1.00
COLL:
0.00
HQY:
6.59
COLL:
1.41
HQY:
3.74
COLL:
3.88
HQY:
$912.18M
COLL:
$486.53M
HQY:
$559.14M
COLL:
$285.89M
HQY:
$255.15M
COLL:
$193.98M
Returns By Period
As of year-to-date, both investments have demonstrated similar returns, with HQY at -4.82% and COLL at -4.82%. Over the past 10 years, HQY has outperformed COLL with an annualized return of 12.99%, while COLL has yielded a comparatively lower 7.96% annualized return.
HQY
-4.82%
18.97%
-6.04%
17.07%
9.45%
12.99%
COLL
-4.82%
7.32%
-21.43%
-28.35%
4.91%
7.96%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
HQY vs. COLL — Risk-Adjusted Performance Rank
HQY
COLL
HQY vs. COLL - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for HealthEquity, Inc. (HQY) and Collegium Pharmaceutical, Inc. (COLL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
HQY vs. COLL - Dividend Comparison
Neither HQY nor COLL has paid dividends to shareholders.
Drawdowns
HQY vs. COLL - Drawdown Comparison
The maximum HQY drawdown since its inception was -60.65%, smaller than the maximum COLL drawdown of -73.59%. Use the drawdown chart below to compare losses from any high point for HQY and COLL. For additional features, visit the drawdowns tool.
Volatility
HQY vs. COLL - Volatility Comparison
HealthEquity, Inc. (HQY) has a higher volatility of 13.13% compared to Collegium Pharmaceutical, Inc. (COLL) at 12.45%. This indicates that HQY's price experiences larger fluctuations and is considered to be riskier than COLL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
HQY vs. COLL - Financials Comparison
This section allows you to compare key financial metrics between HealthEquity, Inc. and Collegium Pharmaceutical, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HQY vs. COLL - Profitability Comparison
HQY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, HealthEquity, Inc. reported a gross profit of 189.04M and revenue of 311.82M. Therefore, the gross margin over that period was 60.6%.
COLL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Collegium Pharmaceutical, Inc. reported a gross profit of 98.29M and revenue of 181.95M. Therefore, the gross margin over that period was 54.0%.
HQY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, HealthEquity, Inc. reported an operating income of 42.15M and revenue of 311.82M, resulting in an operating margin of 13.5%.
COLL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Collegium Pharmaceutical, Inc. reported an operating income of 38.11M and revenue of 181.95M, resulting in an operating margin of 21.0%.
HQY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, HealthEquity, Inc. reported a net income of 26.37M and revenue of 311.82M, resulting in a net margin of 8.5%.
COLL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Collegium Pharmaceutical, Inc. reported a net income of 12.54M and revenue of 181.95M, resulting in a net margin of 6.9%.
Competitive Comparison
See how gross margin, operating margin, and net margin compare for the largest companies in the Health Information Services industry.
| Symbol | Name | Market Cap | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|---|---|
| VEEV | Veeva Systems Inc. | 38.56B | 74.9% | 26.1% | 27.1% |
| GEHC | GE HealthCare Technologies Inc. | 31.76B | 42.1% | 13.2% | 11.8% |
| PME.AX | Pro Medicus Limited | 25.02B | 78.9% | 72.0% | 53.2% |
| 1833.HK | Ping An Healthcare and Technology Company Ltd | 16.06B | — | — | — |
| DOCS | Doximity, Inc. | 11.13B | 91.6% | 47.4% | 44.6% |
| MTHRY | M3 Inc | 8.33B | — | — | — |
| 2158.HK | Yidu Tech Inc | 6.12B | — | — | — |
| RCM | R1 RCM Inc. | 6.04B | — | — | — |
| PRVA | Privia Health Group, Inc. | 2.83B | 10.4% | 1.1% | 1.0% |
| PIAHY | Ping An Healthcare and Technology Company Limited | 2.43B | — | — | — |
HQY vs. COLL - Valuation Comparison
HQY - PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for HQY, comparing it with other companies in the Health Information Services industry. Currently, HQY has a P/E ratio of 83.1. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
COLL - PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for COLL, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, COLL has a P/E ratio of 14.9. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
HQY - PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for HQY compared to other companies in the Health Information Services industry. HQY currently has a PEG ratio of 1.0. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
COLL - PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for COLL compared to other companies in the Drug Manufacturers - Specialty & Generic industry. COLL currently has a PEG ratio of 0.0. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
HQY - PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for HQY relative to other companies in the Health Information Services industry. Currently, HQY has a P/S ratio of 6.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
COLL - PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for COLL relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, COLL has a P/S ratio of 1.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
HQY - PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for HQY in comparison with other companies in the Health Information Services industry. Currently, HQY has a P/B value of 3.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
COLL - PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for COLL in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, COLL has a P/B value of 3.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
User Portfolios with HQY or COLL
11%
YTD
Recent discussions
VUG vs FOCPX
FOCPX vs VUG is absolutely incorrect. I ran the same comparison on Morning star and FOCPX has out performed but your graph shows the opposite.
what is the source of this data. is it trust worthy.
SK
Colors of plots
A lot of the colors used in plotting multiple investments (like the stock comparison graphs) are very close to each other. It's often very difficult to distinguish between them.
Is it possible to change these colors myself? If not, is that a feature in the pipeline?
Thanks
BB
Making constant changes to weights breaks performance numbers
Bee Zee